Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semaxanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 7/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semaxanib SCHEMBL19572 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL19571 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL29373311 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| Semaxanib SCHEMBL28266617 | 1.00 | RET (1.00) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676579 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676595 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL32676489 | 0.87 | RET (0.77) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200799 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL5200796 | 0.85 | KDR (0.74) | RETKDRALKFLT3FLT1 | |
| SCHEMBL8211131 | 0.84 | RET (0.73) | RETKDRALKFLT3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4224 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119950099-B | Method for constructing chronic thromboembolic pulmonary arterial hypertension animal model | 中国医学科学院基础医学研究所 | 2026-05-19 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-12558352-B2 | Use of malic enzyme 1 (ME1) in preparation of drug for preventing and treating pulmonary hypertension (PH) | Institute of Basic Medical Sciences, CAMS (CN) | 2026-02-24 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4676954-A1 | TGF-BETA INHIBITORS FOR USE FOR TREATING RESISTANT OR UNRESPONSIVE CANCER IN PATIENTS | Scholar Rock, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| EP-3218007-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2022-04-06 | — | — | EP | claimed |
| US-20220096502-A1 | TARGETING HYPOXIC CANCER STEM CELLS (CSCS) WITH DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY | LUNELLA BIOTECH, INC. (CA) | 2022-03-31 | — | — | US | claimed |
| US-20220088026-A1 | METHODS OF TREATING TYROSINE KINASE INHIBITOR-INDUCED DIARRHEA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-24 | — | — | US | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| US-20220088029-A1 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | SENHWA BIOSCIENCES INC (TW) | 2022-03-24 | — | — | US | claimed |
| CN-114206435-A | Treatment of central nervous system disorders | 诺欧生物有限责任公司 | 2022-03-18 | — | — | CN | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20220041704-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | IN3BIO LTD. (BM) | 2022-02-10 | — | — | US | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-11229657-B2 | Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy | LUNELLA BIOTECH, INC. (CA) | 2022-01-25 | — | — | US | claimed |